CONDUCT A PHASE 2B EFFICACY STUDY AS PRESCRIBED IN AOI15 WITH COVILIV A PROPRIETARY LIVE ATTENUATED VIRUS COVID-19 VACCINE.
$57,630,647
| Recipient | CODAGENIX INC UEI TEMNL437K2F1 |
|---|---|
| Award ID | 75A50123C00048 |
| Award amount | $57,630,647 |
| Award type | DEFINITIVE CONTRACT |
| Awarding agency | Department of Health and Human Services — Office of Assistant Secretary for Preparedness and Response |
| NAICS | 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) |
| PSC | AN42 |
| Start date | Sep 30, 2023 |
| End date | Mar 31, 2024 |
| Place of performance | FARMINGDALE, NY |
| Record updated | Jun 12, 2024 |
View the official award record
Our catalog shows awards of $250K+ active within the last 5 years. Need older history or smaller awards? Tell us what you need — we expand by request.
Awards tell you who won. Bids tell you what's next. BidCatch scans 100+ federal, state, and local sources every night and sends the new opportunities matching your trade — before they're awarded to someone else. Free for 14 days, then $49.99/month.
Search open bids